CG Oncology Inc.

CGON • Biotechnology

$74.67

— 0.00 (0.00%)

ResultadosÚltimo reporte: 31 mar 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$6.31B

Crecimiento

-23.9%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.01Liquidez saludable · 24.63Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 8 may 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:36 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$74.67

Change0.00%

Shares Out84.52M

Market Cap$6.31B

Enterprise Value$5.24B

52W Range23.65 - 75.50

Beta0.70

P/E-33.79

P/S1,244.53

P/B5.78

P/FCF-39.34

EV/Sales1,033.79

Price$74.67

Change0.00%

Shares Out84.52M

Market Cap$6.31B

Enterprise Value$5.24B

52W Range23.65 - 75.50

Beta0.70

P/E-33.79

P/S1,244.53

P/B5.78

P/FCF-39.34

EV/Sales1,033.79

EV/EBITDA-26.48

EV/FCF-32.68

Earnings Yield-2.96%

FCF Yield-2.54%

Dividend Yield0.00%

Gross Margin-15.02%

Oper. Margin-47.22%

Profit Margin-39.85%

Debt/Eq0.01

Current Ratio24.63

Quick Ratio24.58

Revenue 5Y-23.85%

Target$87.20

Target Upside16.78%

Target Median$85.00

Target Range80.00 - 100.00

Volume846.57K

Avg Volume1.03M

EPS Surprise-0.13

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

44/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.01Liquidez saludable · 24.63Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

CGON

Analyst sentiment

Based on 10 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Precio objetivo

2026-06-24

Bajo

$70.00

Promedio

$82.57

Mediana

$82.00

Alto

$93.00

Resumen de la compañía

IPO: 1/25/2024

Industria: Biotechnology

P/B i: 5.78

Deuda / Patrimonio i: 0.01

Margen operativo: -4722.13%

Margen neto: -3985.02%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.01

Ratio corriente: 24.63

Ratio rápido: 24.58

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

POST LEONARD E

Transacción: 06/22/2026

VENTA

Cambio

-5,000

Precio

$65.00

Presentación

06/23/2026

Tipo

VENTA

POST LEONARD E

Transacción: 06/22/2026

VENTA

Cambio

-5,000

Precio

$0.60

Presentación

06/23/2026

Tipo

VENTA

Mulay James

Transacción: 06/15/2026

VENTA

Cambio

-1,310

Precio

$60.12

Presentación

06/16/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
POST LEONARD E	VENTA	-5,000	$65.00	06/22/2026	06/23/2026
POST LEONARD E	VENTA	-5,000	$0.60	06/22/2026	06/23/2026
Mulay James	VENTA	-1,310	$60.12	06/15/2026	06/16/2026
Mulay James	VENTA	-654	$3.72	06/15/2026	06/16/2026
Graf Susan E	COMPRA	+9,354	$56.09	06/04/2026	06/05/2026
POST LEONARD E	VENTA	-1,000	$54.50	06/04/2026	06/05/2026
Rossi Christina	COMPRA	+9,354	$56.09	06/04/2026	06/05/2026
POST LEONARD E	COMPRA	+9,354	$56.09	06/04/2026	06/05/2026
Mulay James	COMPRA	+9,354	$56.09	06/04/2026	06/05/2026
Tong Victor Edward Jr	COMPRA	+9,354	$56.09	06/04/2026	06/05/2026
Liu Brian Guan-Chyun	COMPRA	+9,354	$56.09	06/04/2026	06/05/2026
Mulay James	VENTA	-15,600	$36.63	04/17/2026	04/20/2026
Mulay James	VENTA	-15,600	$73.01	04/17/2026	04/20/2026
Kuan Arthur	COMPRA	+271,600	$67.68	04/15/2026	04/16/2026
DETORE JAMES M.	COMPRA	+90,574	$67.68	04/15/2026	04/16/2026
Patterson Joshua F.	COMPRA	+45,266	$67.68	04/15/2026	04/16/2026
Kasturi Vijay	COMPRA	+79,216	$67.68	04/15/2026	04/16/2026
Bellete Ambaw	COMPRA	+107,508	$67.68	04/15/2026	04/16/2026
Mulay James	VENTA	-1,310	$63.50	03/16/2026	03/17/2026
Mulay James	VENTA	-654	$3.72	03/16/2026	03/17/2026

Sobre la compañía

CG Oncology Inc.

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.

Fuente - Link

Competidores

AAPG APGE CELC CNTA IRON LEGN RARE TARS TVTX XENE

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

15 Stocks to Watch With Short Squeeze Potential

Bond yields have the entire stock market on edge. The last thing most investors are thinking about is short squeezes, which means maybe they should be something contrarian trades have on their radar.

Schaeffers Research

CG Oncology to Present at Upcoming Investor Conferences in September

DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City this month. The details of the upcoming events are as follows:

GlobeNewsWire

Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. ( NASDAQ: CGON) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

PRNewsWire

CG Oncology: Circling Back After Huge Rally

CG Oncology is advancing cretositimogene grenadenorepvec (cret) for NMIBC, showing strong efficacy and best-in-class safety versus competitors. Cret achieved a 75% anytime CR, 46% 12-month CR, and 42% 24-month CR in BOND-003 Cohort C, with no Grade 3+ adverse events. Rolling BLA for cret in HR BCG-unresponsive NMIBC is expected to complete in 4Q26, with multiple trial readouts in 2H26 and 2027.

Seeking Alpha

CG Oncology, Inc. $CGON Shares Bought by California State Teachers Retirement System

California State Teachers Retirement System increased its stake in CG Oncology, Inc. (NASDAQ: CGON) by 23.6% during the quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,499 shares of the company's stock after purchasing an additional 9,841 shares during the

Defense World

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-08	-0.58	-0.71	-0.13
2026-02-27	-0.61	-0.51	0.1
2025-11-14	-0.55902	-0.57	-0.01098
2025-08-08	-0.49	-0.54	-0.05
2025-05-13	-0.39	-0.45	-0.06
2025-03-28	-0.41	-0.48	-0.07
2024-08-08	-0.42	-0.28	0.14
2024-05-09	-0.35	-0.36	-0.01